Concentra acquires struggling small-molecule biotech Kronos

With the walls quickly closing in, Kronos Bio has accepted a buyout from notorious biotech acquirer Concentra Biosciences.

Tang Capital Partners’ Concentra inked a definitive deal to acquire Kronos’ common stock for a bargain price of 57 cents per share, 35% below the biotech's closing price of 89 cents on Wednesday.